The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research

Launched by INVIVOSCRIBE, INC. · Jan 15, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on using leftover samples from patients who have undergone testing for hematologic diseases, such as blood disorders. The samples, which may include blood, bone marrow, or tissue, will help researchers better understand these conditions and improve future treatments. The trial is currently not recruiting participants, but it aims to collect samples from adults aged 18 and older whose specimens have already been sent to LabPMM, a laboratory that conducts clinical testing.

To be eligible for this study, individuals must have had their blood or tissue samples sent to LabPMM for testing. However, if their samples were obtained from another source or have already been used in another clinical study, they would not qualify. Participants can expect that their de-identified (meaning their personal information will not be attached) samples will be used solely for research purposes, contributing to advancements in understanding and treating hematologic diseases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Specimen/sample, peripheral blood (PB), bone marrow (BM), genomic DNA (gDNA) and/or formalin-fixed paraffin-embedded tissue (FFPE) from patients whose specimens/samples have been sent to LabPMM for clinical testing
• • 2. Donor Age ≥ 18 years
• Exclusion Criteria:
• • 1. Sample/specimen has been obtained from a third-party vendor with a Materials Transfer Agreement (MTA) on file with LabPMM
• • 2. The specimens/samples have previously been enrolled in a clinical study